Bausch Health Companies (BHC) Return on Capital Employed (2010 - 2026)
Bausch Health Companies (BHC) reported Return on Capital Employed of 2.81% for Q1 2026, down 413.0% on a YoY basis from 0.9% in Q1 2025, and down 65.28% sequentially from 8.09% in Q4 2025.
Bausch Health Companies (BHC) Return on Capital Employed (2010 - 2026) Analysis & Trends
Bausch Health Companies (BHC) has 17 years of Return on Capital Employed data on file, last reported at 2.81% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 413.0% year-over-year to 2.81%; the trailing twelve-month figure through Mar 2026 stood at 2.81% (down 413.0% YoY), and the FY2025 full-year result was 8.14%, up 48.0% from the prior year.
- Return on Capital Employed slipped to 2.81% in Q1 2026, from 8.09% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 8.53% in Q3 2025 to a low of 1.59% in Q1 2023.
- A 5-year average of 4.92% and a median of 4.68% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 602 bps in 2022 and slumped 413 bps in 2026, its largest moves.
- Tracing BHC's Return on Capital Employed over 5 years: stood at 2.06% in 2022, then jumped by 104 bps to 4.2% in 2023, then jumped by 86 bps to 7.82% in 2024, then advanced by 3 bps to 8.09% in 2025, then tumbled by 65 bps to 2.81% in 2026.
- Business Quant data shows BHC's Return on Capital Employed at 2.81% in Q1 2026, 8.09% in Q4 2025, and 8.53% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Bausch Health Companies | 1.66 Bn | 1.33 Bn | 2.52 Bn | 2.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.81% |
| Dec 31, 2025 | 8.09% |
| Sep 30, 2025 | 8.53% |
| Jun 30, 2025 | 7.30% |
| Mar 31, 2025 | 6.94% |
| Dec 31, 2024 | 7.82% |
| Sep 30, 2024 | 6.13% |
| Jun 30, 2024 | 4.68% |
| Mar 31, 2024 | 4.70% |
| Dec 31, 2023 | 4.20% |
| Sep 30, 2023 | 1.65% |
| Jun 30, 2023 | 2.77% |
| Mar 31, 2023 | 1.59% |
| Dec 31, 2022 | 2.06% |
| Sep 30, 2022 | 4.52% |
| Jun 30, 2022 | 5.87% |
| Mar 31, 2022 | 3.92% |
| Dec 31, 2021 | 1.87% |
| Sep 30, 2021 | 0.32% |
| Jun 30, 2021 | -0.15% |